CHARLES MIKULKA: Open Payments
NPI 1801676333 · WILMINGTON, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$601 in 22 payments from 9 companies in 2025. Trend: 2023 $0 · 2024 $309 · 2025 $601
Food & beverage: $601
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 3 | $176 |
| PFIZER INC. | 5 | $90 |
| GENZYME CORPORATION | 3 | $82 |
| Janssen Biotech, Inc. | 2 | $62 |
| Ardelyx, Inc. | 2 | $57 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $42 |
| ABBVIE INC. | 2 | $40 |
| Lilly USA, LLC | 2 | $32 |
| Novo Nordisk Inc | 1 | $20 |
Products named: REZDIFFRA, VELSIPITY, DUPIXENT, TREMFYA, IBSRELA, XIFAXAN, OMVOH, RINVOQ.
Industry payments across DE — which companies pay providers there.
